ClinicalTrials.gg
Drug

Crizanlizumab clinical trials

Also written SEG101.

studies test it
13
open now
4
in phase 3
2
first study started
2013

How each study uses crizanlizumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the crizanlizumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
15 Nov 2019 · ADAKVEO · BLA 761128 (FDA, Drugs@FDA)
European Union
28 Oct 2020 · Adakveo · EMEA/H/C/004874 (EMA; now revoked)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Crizanlizumab
10

Brand

ADAKVEO
1

Development codes

SEG101
7
SelG1
1

Studies by the year they started

13 studies that test it; most in 2019 (3)

Studies that test crizanlizumab, by start year
YearStudies
20131
20171
20181
20193
20201
20213
20231
20242

By phase

A phase 1/2 study counts in both.

Phase 1
1
Phase 2
9
Phase 3
2
Phase 4
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 9 · Other 4

Novartis Pharmaceuticals (8) · Washington University School of Medicine (1) · Johns Hopkins University (1) · Reprixys Pharmaceutical Corporation (1) · Children's Hospital Los Angeles (1) · Sheba Medical Center (1)

Often tested with

Tested in the same studies.

Nivolumab (1)

Studies

Open first, then newest update. How each study uses crizanlizumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 13

Given beside what is tested · 1 — crizanlizumab is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with crizanlizumab

Codes

What other systems call crizanlizumab · ClinicalTrials.gg INT000604

  • MeSH (NLM) C000614139crizanlizumabConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) L7451S9126CRIZANLIZUMABConfirmed FDA, NLM, Wikidata
  • RxNorm 2262279One source FDA
  • Wikidata Q28209568crizanlizumabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C133543CrizanlizumabOne source FDA
  • DrugBank DB15271One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.